Back to Search
RUBEN ALEXANIAN, M.D.
M.D.
Interventional Cardiology Physician
NPI: 1760748354IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease Physician
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
61628-20(WI)
Interventional Cardiology PhysicianPrimary
Internal Medicine — Interventional Cardiology
Code: 207RI0011X
61628(WI)
CMS Specialties
PrimaryINTERVENTIONAL CARDIOLOGY
Education
UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE
Class of 2012
Research & Publications (20)
CR represents an early index of potential long survival in multiple myeloma.
PMID 19633690·Bone Marrow Transplant·2010
8-other
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
PMID 18783399·Br J Haematol·2008
3-trial
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
PMID 17448913·Biol Blood Marrow Transplant·2007
8-other
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
PMID 17558699·Hematology·2007
3-trial
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PMID 16754936·J Clin Oncol·2006
3-trial
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
PMID 15690325·Cancer·2005
4-observational
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
PMID 16206291·Cancer·2005
3-trial
Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.
PMID 16087694·Ann Oncol·2005
8-other
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
PMID 15981221·Am J Hematol·2005
3-trial
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.
PMID 15970928·Br J Cancer·2005
8-other
Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy.
PMID 14730336·Bone Marrow Transplant·2004
8-other
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
PMID 15461622·Br J Haematol·2004
3-trial
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
PMID 15370250·Leuk Lymphoma·2004
3-trial
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
PMID 15197803·Cancer·2004
4-observational
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma.
PMID 15170166·Bone Marrow Transplant·2004
8-other
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.
PMID 15160952·Leuk Lymphoma·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1575 BEAM AVE
MAPLEWOOD, MN 55109 - Phone
- (612) 672-1525
Quick Facts
- NPI
- 1760748354
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile